: An Experimental, One-Time Gene Therapy for Parkinson’s Disease If your response to Parkinson’s disease medications has...see more become unpredictable or isn’t what it used to be, this clinical study may be an option that you should discuss with your doctor. The RESTORE-1 Clinical Study is evaluating an experimental, one-time gene therapy approach to […]

Read More

In September, APDA announced funding for cutting-edge research projects for the 2019-2020 academic year totaling $1.7 million....see more These grants, along with others that were submitted, were reviewed earlier this year by APDA’s Scientific Advisory Board (SAB). The annual SAB meeting is also a time to hear updates on previously-funded research. David Standaert, MD, […]

Read More

2019 World Parkinson Congress Highlights: A world away, but so close together No matter where we find ourselves –...see more at home in our headquarters office in New York, at one of our APDA Chapter events in Oklahoma or Wisconsin, at an industry event in California, or all the way across the globe at the World Parkinson […]

Read More

 New Program Offers Creative Outlet, Improves PD Symptoms  An innovative new...see more program offers a host of benefits for people with Parkinson’s who have challenges in visual perception and spatial relations, affecting their ability to move through the world. Most current PD treatment regimens don’t focus on this […]

Read More

  Beyond the Doctor’s Visit: Taking Parkinson’s Care to the Next Level “Game changing.” That’s how Robin...see more Kornhaber, Senior Vice President, National Programs and Partnerships at the American Parkinson Disease Association (APDA), describes APDA Information and Referral (I&R) Centers. APDA I&R Centers are at medical institutions across the country where APDA supports either […]

Read More